Avience Biomedicals Ltd.
AVIENCESME
Ask IPO
Overview
Avience Biomedicals Limited is a Noida-based medical consumables and diagnostics company engaged in manufacturing in-vitro diagnostic products and medical devices, while also trading and distributing diagnostic equipment. Avience Biomedicals began with essential diagnostic kits such as VTM, COVID, HIV, HBsAg, malaria and dengue tests, and has expanded into serology products, biochemistry analysers, biochemistry reagents, electrolyte analysers, culture media, plasticware and other lab consumables. The company serves B2B, B2C and government customers including pathology labs, microbiology labs, hospitals and research centres, supported by quality certifications such as ISO 9001, ISO 13485, GMP and MSME ZED Gold.
Opening Date
Jun 18, 2026
Closing Date
Jun 22, 2026
Listing Date
Jun 25, 2026
IPO Type
SME
IPO Status
Open
Issue Size
30.24 Cr
Fresh Issue
30.24 Cr
Offer for Sale
0 Cr
Price Band
₹196 - ₹208
Lot Size
600
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
The main objectives of the issue are to support capacity expansion, strengthen working capital and fund general corporate needs.
- •
Part finance the capital expenditure for setting up a new manufacturing unit at Industrial Plot No. 70, Sector 28, Medical Device Park under YEIDA, Gautam Buddha Nagar, Uttar Pradesh, including construction, utilities and production infrastructure needed to expand manufacturing operations.
- •
Fund the company’s working capital requirements to support higher procurement of raw materials, inventory build-up, supplier advances, receivables growth and day-to-day operational needs as sales scale up through the existing and proposed facilities.
- •
Meet general corporate purposes, including strategic initiatives, brand building, marketing expansion, business development, operational strengthening, contingencies and any shortfall in funding the stated objects within regulatory limits.
Key Performance Indicator
P/E Ratio
11.59
EPS
17.94
ROE
22.38%
ROCE
16.99%
RONW
22.38%
Debt to Equity Ratio
—
PAT Margin
—
EBITDA Margin
24.7%
P/B
2.94
SWOT Analysis
Strengths
- •
Diverse diagnostics and medical consumables portfolio spanning rapid test kits, reagents, analysers, culture media and laboratory consumables.
- •
Established presence across B2B, B2C and government channels, serving pathology labs, hospitals, research centres and public procurement programs.
- •
Multiple quality and compliance credentials including ISO 9001, ISO 13485, GMP and MSME ZED Gold, supporting credibility in regulated healthcare markets.
- •
Growing manufacturing capability supported by product license additions, export registrations and planned expansion at the YEIDA Medical Device Park.
Weaknesses
- •
Business remains working-capital intensive, with rising receivables and inventory levels requiring continued funding support.
- •
A substantial portion of revenue still comes from trading activities, which can limit margin expansion compared with owned manufacturing.
- •
Operations and manufacturing footprint are currently concentrated mainly around Noida and the planned new facility, increasing location dependency.
- •
The company is still scaling in a highly regulated industry where delays in approvals, licenses or commissioning can affect growth timelines.
Opportunities
- •
New YEIDA manufacturing facility can materially increase installed capacity, improve automation and support a broader product portfolio.
- •
Rising demand in India for diagnostics, medical devices and affordable healthcare solutions creates scope for domestic market expansion.
- •
Export growth opportunities can improve as the company pursues WHO-compliant infrastructure, international certifications and overseas registrations.
- •
Government support for medical device manufacturing, healthcare infrastructure and Make in India can benefit local production and procurement demand.
Threats
- •
The medical devices and diagnostics industry faces evolving regulatory requirements, certification demands and compliance risks in India and export markets.
- •
Competition from established multinational and domestic players may pressure pricing, market share and customer acquisition.
- •
Dependence on timely access to raw materials, imported components and equipment can expose the business to supply chain disruptions and cost volatility.
- •
Macroeconomic slowdown, inflation, geopolitical tensions or adverse public health and policy developments could affect demand, margins and financing conditions.
Subscription Rate
Frequently Asked Questions about Avience Biomedicals Ltd.
Avience Biomedicals Limited is a Noida-based medical consumables and diagnostics company engaged in manufacturing in-vitro diagnostic products and medical devices, while also trading and distributing diagnostic equipment. Avience Biomedicals began with essential diagnostic kits such as VTM, COVID, HIV, HBsAg, malaria and dengue tests, and has expanded into serology products, biochemistry analysers, biochemistry reagents, electrolyte analysers, culture media, plasticware and other lab consumables. The company serves B2B, B2C and government customers including pathology labs, microbiology labs, hospitals and research centres, supported by quality certifications such as ISO 9001, ISO 13485, GMP and MSME ZED Gold.
The Avience Biomedicals Ltd. IPO is scheduled to open for subscription on Jun 18, 2026 and close on Jun 22, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Avience Biomedicals Ltd. IPO is ₹196 to ₹208. Investors can place bids within this range once the issue opens.
The minimum lot size for the Avience Biomedicals Ltd. IPO is 600 shares. The minimum investment amount ₹1,24,800.
The total issue size of the Avience Biomedicals Ltd. IPO is approximately ₹30.24. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Avience Biomedicals Ltd. IPO has been subscribed 10.75 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Avience Biomedicals Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Avience Biomedicals Ltd. are expected to list on stock exchanges on Jun 25, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Avience Biomedicals Ltd. IPO are proposed to be used for The main objectives of the issue are to support capacity expansion, strengthen working capital and fund general corporate needs., Part finance the capital expenditure for setting up a new manufacturing unit at Industrial Plot No. 70, Sector 28, Medical Device Park under YEIDA, Gautam Buddha Nagar, Uttar Pradesh, including construction, utilities and production infrastructure needed to expand manufacturing operations., Fund the company’s working capital requirements to support higher procurement of raw materials, inventory build-up, supplier advances, receivables growth and day-to-day operational needs as sales scale up through the existing and proposed facilities., Meet general corporate purposes, including strategic initiatives, brand building, marketing expansion, business development, operational strengthening, contingencies and any shortfall in funding the stated objects within regulatory limits.
Before applying for the Avience Biomedicals Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
